Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.120
+0.070 (6.67%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Fate Therapeutics Employees
Fate Therapeutics had 181 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
181
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$75,309
Profits / Employee
-$1,029,072
Market Cap
127.20M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
FATE News
- 4 days ago - Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE) - GlobeNewsWire
- 16 days ago - Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - GlobeNewsWire
- 6 weeks ago - Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Fate Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap - Seeking Alpha
- 4 months ago - Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus - GlobeNewsWire
- 5 months ago - Fate Therapeutics Announces Leadership Transition - GlobeNewsWire